Another study using an AMPK activator, thienopyridone-derived compound GSK621, in AML also supported the disconnection between AMPK and mTOR with sustained mTOR activation, even after AMPK activation by GSK621 [28]. Here, MTOR is linked to acute myeloid leukemia.